Bellerophon Therapeutics Inc

Bellerophon Therapeutics — Technical Presentation (December 2019)

10 slides from Bellerophon Therapeutics's technical presentation, Dec 17, 2019

  1. Slide 1: iNO-PF Cohort 2 Top-Line Data Call

    Bellerophon Therapeutics iNO-PF Cohort 2 Top-Line Data Call December 17, 2019 Nasdaq: BLPH

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financi

  3. Slide 3: iNO-PF Cohort 2 Top-Line Results

    iNO-PF Cohort 2 Top-Line Results • Statistically and clinically significant placebo corrected improvement of 14 minutes/day in MVPA • Consistent and meaningful benefit in overall activity • Clinically meaningful benefit in SGRQ and UCSD demonstrating improvement in quality of life and dyspnea • Puls

  4. Slide 4: Statistically Significant Benefit Over Placebo Demonstrated in MVPA

    Statistically Significant Benefit Over Placebo Demonstrated in MVPA p=0.02 • Placebo corrected improvement of 14 min/day at month 4 • Baseline: 74 min/day • Primary endpoint for Phase 3 Cohort • MVPA = moderate to vigorous physical activity • Data points and error bars = mean and standard error • Co

  5. Slide 5: Consistent and Meaningful Benefit Exhibited in Overall Activity

    Consistent and Meaningful Benefit Exhibited in Overall Activity • Placebo corrected improvement of 100 counts/min at month 4 • Baseline: 1476 counts/min • Data points and error bars = mean and standard error • Cohort 2: n=44; randomized 2:1 5

  6. Slide 6: St. George's Respiratory Questionnaire (SGRQ) Indicates QOL Benefit in Multiple Measures

    St. George’s Respiratory Questionnaire (SGRQ) Indicates QOL Benefit in Multiple Measures Increased score indicative of worsening • Placebo corrected improvement of 3 points • Placebo corrected improvement of 5 points • Placebo corrected improvement of 6 points • Measures health status and quality of

  7. Slide 7: UCSD Shortness of Breath Questionnaire (SOBQ) Indicates Benefit in Dyspnea

    UCSD Shortness of Breath Questionnaire (SOBQ) Indicates Benefit in Dyspnea Increased score indicative of worsening • Placebo corrected improvement of 5 points • Measures shortness of breath while patients perform daily physical activity • Data points and error bars = mean and standard error • Change

  8. Slide 8: Safety Summary

    Safety Summary iNO 45 Placebo n=30 n=14 • Pulsed Inhaled Nitric Oxide was well- tolerated in Cohort 2 Total Adverse Events Reported 26 (0.87/subject) 9 (0.64/subject) • Incidence of AEs and SAEs was low in both active and placebo groups Total Serious Adverse Events 5 (0.17/subject) 7 (0.50/subject)

  9. Slide 9: Next Steps in PH-ILD

    Next Steps in PH-ILD • Results from Cohort 2 support continuing program into Phase 3 with MVPA as primary endpoint • Phase 3 initiation expected in 1Q2020 upon selection of dose and confirmation of trial size • Company entered into $10M convertible financing facility with existing institutional inve

  10. Slide 10: Investor Contacts

    Investor Contacts Fabian Tenenbaum Chief Executive Officer [email protected] Brian Ritchie LifeSci Advisors [email protected] 212-915-2578

Bellerophon Therapeutics — Technical Presentation (December 2019) on 6ix